Affomix to provide antibodies for Kalgene’s companion diagnostics program

Register for free to listen to this article
Listen with Speechify
BRANFORD, Conn.—Affomix Corp., a developer of automated,high-throughput monoclonal antibody selection technology, announced in lateDecember that it will use its Y2HExpress technology to select antibodies withpotential diagnostic and therapeutic utility in breast cancer for KalgenePharmaceuticals Inc., a private company focused on the development of oncologytherapeutics and companion diagnostics. Under the agreement, Affomix will useY2HExpress for the selection of single-chain antibodies for Kalgene, whoseportfolio of oncology products is at various stages in development, from assaydevelopment to advanced clinical trials. Financial terms of the serviceagreement were not disclosed, nor were the financial milestones related todiagnostic and therapeutic applications.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue